Viewing Opinion | StockChase
stockchase picture

Compiling comments that experts make about stocks while on public TV.

2017-04-20

Opinion for AbbVie Inc. (ABBV-N)

Signal Price Bias Subject Owned
PAST TOP PICK $63.780 UNKNOWN DIVIDEND STOCKS AND MACRO STRATEGIES Yes

(A Top Pick Dec 23/16. Up 4%.) A one trick pony with their drug Humira. Valuation is quite reasonable and is going to be 12-13X projected earnings. A lot of that is based on sales of Humira, a life altering drug, which accounts for over 60% of their revenues. Made 2 very large acquisitions in the past few years, and we are starting to see some of those drugs in the pipeline getting approved.

Lorne Zeiler
Portfolio Manager & Wealth Advisor, TriDelta Financial

No Comments.


You must be logged in to comment.